Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 241

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 241
---
 Shares may be made available from Shares held in treasury
or authorized but unissued shares of the Company not reserved for any other purpose. To date, no shares have been awarded under this
Plan.

On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (“2025 Securities Purchase Agreement”) with JAK, pursuant to which, amongst
other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal amount
of $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may require
the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original principal
amount for all additional convertible notes shall not exceed $25,600,000).

On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor, At
the closing of the fourth tranche, the Company sold to the investor a senior convertible note in the principal amount of $2,000,000.
The Note bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.

Mr. Yip Eng Jeremy Foo,
a director of NewGenIvf Group Limited (the “Company”), has resigned from the Board of Directors of the Company, the Audit
Committee of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4, 2025. Mr. Foo’s
resignation did not result from any disagreement with the Board or the Company on any matter relating to the Company’s operations,
policies or practices.

Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo’s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured